Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension [F3061, F3064, L5146]. Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146].
Marketing Status approved
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 82231-114; 54893-0020; 63190-0350; 63629-8840; 61556-040; 64181-0028; 51407-731; 60505-0593; 63629-8839; 24002-0022; 65035-131; 68245-0003; 0781-6185; 40016-006; 0078-0946; 55359-540; 65129-1207
UNII WJ68R08KX9
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye allergy06.04.05.010; 10.01.03.0280.000624%-
Eye discharge06.04.05.0010.000716%-
Eye disorder06.08.03.0010.003086%-
Eye haemorrhage06.07.02.001; 12.02.02.012; 24.07.05.0020.000184%-
Eye inflammation06.04.05.0020.000716%-
Eye irritation06.04.05.0030.020406%-
Eye pain06.08.03.0020.007861%
Eye swelling06.08.03.0030.001249%-
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003---
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.001525%-
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Glaucoma06.03.01.0020.002204%
Hair colour changes23.02.06.001--
Hair growth abnormal23.02.06.006---
Hair texture abnormal23.02.06.004--
Halo vision06.02.06.003---
Headache17.14.01.001--
Heart rate irregular13.14.04.003---
Herpes simplex11.05.02.001; 23.11.05.004---
Hyperaemia24.03.02.0020.000624%-
Hypercholesterolaemia14.08.01.001---
Hypersensitivity10.01.03.0030.003178%
Hypertension24.08.02.0010.000863%
Hypertrichosis23.02.04.002--
Hypoaesthesia eye06.01.01.007; 17.02.06.019---
Hypotension24.06.03.002--
Hypotony of eye06.08.03.0040.000276%-
Immune system disorder10.02.01.001---
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages